A New Rapid Method for Clostridium difficile DNA Extraction and Detection in Stool

Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
The Journal of molecular diagnostics: JMD (Impact Factor: 4.85). 03/2012; 14(3):274-9. DOI: 10.1016/j.jmoldx.2012.01.003
Source: PubMed


We describe a new method for the rapid diagnosis of Clostridium difficile infection, with stool sample preparation and DNA extraction by heat and physical disruption in a single-use lysis microreactor (LMR), followed by a rapid PCR amplification step. All steps can be accomplished in <20 minutes overall. Gel electrophoresis is currently used to detect the amplification product, pending real-time availability with an ultra-rapid thermocycler. Compared with the dual enzyme immunoassay (EIA) screening test (C. diff Quik Chek Complete; Techlab, Blacksburg, VA), the novel LMR/PCR assay showed complete concordance with all glutamate dehydrogenase (GDH) results (GDH(+)/toxin(+), n = 48; GDH(-)/toxin(-), n = 81). All 69 stool samples with discordant EIA results (GDH(+)/toxin(-)) were tested by both the LMR/PCR assay and the loop-mediated isothermal amplification test (LAMP) (Illumigene C. difficile; Meridian Bioscience, Cincinnati, OH). In 64/69 EIA-discordant samples, LAMP and LMR/PCR results matched (both positive in 29 sample and both negative in 35 samples); in the remaining 5 samples, results were discrepant between the LAMP assay (all five negative) and the LMR/PCR assay (all 5 positive). Overall, LMR/PCR testing matched the current algorithm of EIA and/or LAMP reflex testing in 193/198 (97.5%) samples. The present proof-of-concept study suggests that the novel LMR/PCR technique described here may be developed as an inexpensive, rapid, and reliable point-of-care diagnostic test for C. difficile infection and other infectious diseases.

423 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Always use detection: Signal amplification from DNAzymes was combined with gold nanoparticles (GNPs) to give a simple and sensitive colorimetric assay for various genetic targets. The assay has 50 pM sensitivity without the need for purification steps and can detect multiple targets in parallel. This was applied to rapidly detect gonorrhea, syphilis, malaria, and hepatitis B infections.
    Angewandte Chemie International Edition 03/2013; 52(11):3168-71. DOI:10.1002/anie.201208715 · 11.26 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Rapid, specific and sensitive diagnosis of infectious diseases is important for the rational, effective and economic treatment of the infection. Focused treatment of the patient with an accurate diagnosis may also contribute to the minimization of drug resistance development. Rapidly evolving micro and nanotechnologies contribute to the development of new diagnostic modalities. This critical review provides an overview of current developments in diagnostics for infectious disease enabled by nanotechnologies and includes a range of representative examples.
    European Journal of Nanomedicine 03/2014; DOI:10.1515/ejnm-2014-0004
  • [Show abstract] [Hide abstract]
    ABSTRACT: Toxigenic Clostridium difficile is a major pathogen causing nosocomial diarrhea. Consequently, rapid detection of toxigenic C. difficile is very important in clinical laboratories. The illumigene C. difficile DNA amplification assay (illumigene; Meridian Bioscience, Inc., Cincinnati, OH) is a rapid method that detects the toxin A gene (tcdA) by loop-mediated isothermal amplification. In the present study, we evaluated the diagnostic performance of the illumigene assay using 302 consecutive stool specimens in comparison with the VIDAS C. difficile A&B enzyme-linked fluorescent immunoassay (VIDAS-CDAB; BioMerieux SA, France). Toxigenic culture was used as the reference method. The sensitivity, specificity, positive predictive value, and negative predictive value of the illumigene assay were 88.1%, 96.7%, 86.7%, and 97.1%, respectively, while those of the VIDAS-CDAB assay were 40.4%, 98.8%, 87.5%, and 88.5%, respectively. It is of note that use of a combination of the illumigene and VIDAS-CDAB assays did not improve any of the four evaluated parameters (88.1%, 95.5%, 82.5%, and 97.1%, respectively). The illumigene assay showed limits of detection of 250 and 11,467 CFU/mL for ATCC 9688 (tcdA+, tcdB+, cdtB-) and ATCC 43598 (tcdA-, tcdB+, cdtB-) reference strains, respectively, and there was no cross-reactivity with eight frequently isolated bacteria species. In conclusion, the illumigene assay might be a useful method for rapid detection of toxigenic C. difficile in clinical laboratories. Additionally, the VIDAS-CDAB assay seems unnecessary if the illumigene assay is used.
    Diagnostic Microbiology and Infectious Disease 09/2014; 80(3). DOI:10.1016/j.diagmicrobio.2014.08.014 · 2.46 Impact Factor